 OTTAWA, Sept. 07, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that CrysvitaTM Burosumab Injection has been approved by Health Canada for the treatment of Tumour Induced Osteomalacia TIO in adults. Crysvita is also approved for the treatment of X-Linked Hypophosphatemia. 